Risk factor
Strong & resilient to price shocks
Profitability factor
Very strong margins and returns
About
Jiangsu Nhwa Pharmaceutical Co., LTD operates as a global pharmaceutical entity, focusing on the research, production, and sale of treatments for the central nervous system, along with cardiovascular and cerebrovascular ailments. Its comprehensive product line includes therapeutics for anesthesia, psychiatry, and neurological disorders. Additionally, the company is a supplier of Active Pharmaceutical Ingredients (APIs), specifically for central nervous system, anesthetic, and sedative applications, among others. The firm was established in 1978 and is based in Xuzhou, China.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair
Target Price
The average target price of 002262.SZ is 26.1 and suggests 30.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to